Rafael Holdings EBITDA Margin Growth & History (RFL)
Rafael Holdings's ebitda margin was −96,236.67% for fiscal 2025.
View full Rafael Holdings company overviewRafael Holdings annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-07-31 | −96,236.67% | −80161.00 pp |
| 2024 | 2024-07-31 | −16,075.67% | −10711.87 pp |
| 2023 | 2023-07-31 | −5,363.80% | +9369.13 pp |
| 2022 | 2022-07-31 | −14,732.93% | −11225.57 pp |
| 2021 | 2021-07-31 | −3,507.36% | −3372.96 pp |
| 2020 | 2020-07-31 | −134.40% | −34.68 pp |
| 2019 | 2019-07-31 | −99.72% | −50.69 pp |
| 2018 | 2018-07-31 | −49.03% | −82.67 pp |
| 2017 | 2017-07-31 | 33.64% | −17.08 pp |
| 2016 | 2016-07-31 | 50.72% | — |
Rafael Holdings quarterly ebitda margin
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q3 2026 | 2026-04-30 | −3,811.17% | −2194.87 pp |
| Q2 2026 | 2026-01-31 | −3,127.96% | +5377.23 pp |
| Q1 2026 | 2025-10-31 | −4,204.58% | −1268.65 pp |
| Q3 2025 | 2025-04-30 | −1,616.30% | +26079.83 pp |
| Q2 2025 | 2025-01-31 | −8,505.19% | −3939.02 pp |
| Q1 2025 | 2024-10-31 | −2,935.94% | +683.18 pp |
| Q4 2024 | 2024-07-31 | −2,289.09% | +1524.14 pp |
| Q3 2024 | 2024-04-30 | −27,696.13% | −23453.88 pp |
| Q2 2024 | 2024-01-31 | −4,566.18% | +1490.97 pp |
| Q1 2024 | 2023-10-31 | −3,619.12% | +3695.17 pp |
| Q4 2023 | 2023-07-31 | −3,813.24% | +2899.81 pp |
| Q3 2023 | 2023-04-30 | −4,242.25% | +1906.43 pp |
| Q2 2023 | 2023-01-31 | −6,057.14% | −3920.66 pp |
| Q1 2023 | 2022-10-31 | −7,314.29% | +18611.89 pp |
| Q4 2022 | 2022-07-31 | −6,713.04% | — |
| Q3 2022 | 2022-04-30 | −6,148.68% | −5817.57 pp |
| Q2 2022 | 2022-01-31 | −2,136.49% | −1054.53 pp |
| Q1 2022 | 2021-10-31 | −25,926.18% | −25731.12 pp |
| Q3 2021 | 2021-04-30 | −331.11% | −209.30 pp |
| Q2 2021 | 2021-01-31 | −1,081.96% | −966.02 pp |
| Q1 2021 | 2020-10-31 | −195.06% | −106.14 pp |
| Q4 2020 | 2020-07-31 | −209.60% | −47.76 pp |
| Q3 2020 | 2020-04-30 | −121.81% | −50.50 pp |
| Q2 2020 | 2020-01-31 | −115.94% | −20.07 pp |
| Q1 2020 | 2019-10-31 | −88.93% | −28.04 pp |
| Q4 2019 | 2019-07-31 | −161.84% | −94.60 pp |
| Q3 2019 | 2019-04-30 | −71.31% | −43.04 pp |
| Q2 2019 | 2019-01-31 | −95.87% | −55.39 pp |
| Q1 2019 | 2018-10-31 | −60.88% | −3.92 pp |
| Q4 2018 | 2018-07-31 | −67.24% | — |
| Q3 2018 | 2018-04-30 | −28.27% | −47.54 pp |
| Q2 2018 | 2018-01-31 | −40.48% | −82.44 pp |
| Q1 2018 | 2017-10-31 | −56.96% | — |
| Q3 2017 | 2017-04-30 | 19.27% | — |
| Q2 2017 | 2017-01-31 | 41.96% | — |
Rafael Holdings ebitda margin trends
Over the last five fiscal years, Rafael Holdings's ebitda margin decreased from −134.40% to −96,236.67%, a change of −96102.27 percentage points. The latest reported quarter, Q3 2026, shows −3,811.17%.
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Rafael Holdings source filings ↗Community posts
Rafael submits remibetadex for FDA review despite a missed pivotal endpoint
Rafael Holdings ($RFL) said its Cyclo Therapeutics subsidiary submitted a US marketing application for remibetadex, also called Trappsol Cyclo, for neurological and internal-organ manifestations of Niemann-Pick disease type C. The proposed ...